Literature DB >> 33478710

Long-Term Outcomes in Patients With a Left Ejection Fraction ≤15% Undergoing Cardiac Resynchronization Therapy.

John Rickard1, Divyang Patel2, Carolyn Park3, Joseph E Marine4, Sunil Sinha4, W H Wilson Tang4, Niraj Varma2, Bruce L Wilkoff4, David Spragg4.   

Abstract

OBJECTIVES: This study aimed to determine the long-term outcomes and predictors of left ventricular (LV) ejection fraction (LVEF) improvement in patients with severe cardiomyopathies undergoing cardiac resynchronization therapy (CRT).
BACKGROUND: Whether patients with severe LV dysfunction benefit from CRT or have reached a point in disease severity past the point at which CRT is beneficial is unknown.
METHODS: We collected clinical and echocardiographic data on 420 patients with an LVEF of ≤15% and a QRS duration of ≥120 ms undergoing CRT at the Cleveland Clinic and 2 hospitals in the Johns Hopkins Health System between April 2003 and May 2014. Multivariate models were created to determine factors associated with response to CRT, defined as an absolute improvement in LVEF of >5% and survival free of LVAD and heart transplant. Procedure-related deaths were also collected.
RESULTS: A total of 298 patients had pre- and appropriately timed post-CRT echocardiograms, of whom 145 (48.7%) met the criteria for response. In multivariate analysis, LV size and left bundle branch block (LBBB) were associated with response. Among the most dilated quintile (LV end-diastolic diameter [LVEDD] of >7.8 cm), 30.4% met the criteria for response. In multivariate analysis, smaller LV end-diastolic dysfunction and presence of LBBB were associated with improved survival free of heart failure and LVAD over a mean follow-up period of 5.2 years. There were no procedure-related deaths.
CONCLUSIONS: Patients with severe LV dysfunction respond to CRT, although at a lower rate compared to traditional CRT candidates. Smaller LV size and LBBB are important predictors of positive outcomes in this population. Even among the most dilated patients, 30.4% realized a meaningful improvement in LVEF with CRT. The CRT implant procedure itself appears well tolerated.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  cardiac resynchronization therapy; reverse remodeling; severe cardiomyopathy; survival

Mesh:

Year:  2020        PMID: 33478710      PMCID: PMC9022441          DOI: 10.1016/j.jacep.2020.07.025

Source DB:  PubMed          Journal:  JACC Clin Electrophysiol        ISSN: 2405-500X


  14 in total

1.  Cardiac resynchronization in chronic heart failure.

Authors:  William T Abraham; Westby G Fisher; Andrew L Smith; David B Delurgio; Angel R Leon; Evan Loh; Dusan Z Kocovic; Milton Packer; Alfredo L Clavell; David L Hayes; Myrvin Ellestad; Robin J Trupp; Jackie Underwood; Faith Pickering; Cindy Truex; Peggy McAtee; John Messenger
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

2.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

Authors:  Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

3.  Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up.

Authors:  Claudia Ypenburg; Rutger J van Bommel; C Jan Willem Borleffs; Gabe B Bleeker; Eric Boersma; Martin J Schalij; Jeroen J Bax
Journal:  J Am Coll Cardiol       Date:  2009-02-10       Impact factor: 24.094

4.  2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA).

Authors:  Michele Brignole; Angelo Auricchio; Gonzalo Baron-Esquivias; Pierre Bordachar; Giuseppe Boriani; Ole-A Breithardt; John Cleland; Jean-Claude Deharo; Victoria Delgado; Perry M Elliott; Bulent Gorenek; Carsten W Israel; Christophe Leclercq; Cecilia Linde; Lluís Mont; Luigi Padeletti; Richard Sutton; Panos E Vardas; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Paulus Kirchhof; Carina Blomstrom-Lundqvist; Luigi P Badano; Farid Aliyev; Dietmar Bänsch; Helmut Baumgartner; Walid Bsata; Peter Buser; Philippe Charron; Jean-Claude Daubert; Dan Dobreanu; Svein Faerestrand; David Hasdai; Arno W Hoes; Jean-Yves Le Heuzey; Hercules Mavrakis; Theresa McDonagh; Jose Luis Merino; Mostapha M Nawar; Jens Cosedis Nielsen; Burkert Pieske; Lidija Poposka; Frank Ruschitzka; Michal Tendera; Isabelle C Van Gelder; Carol M Wilson
Journal:  Eur Heart J       Date:  2013-06-24       Impact factor: 29.983

5.  2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Cynthia M Tracy; Andrew E Epstein; Dawood Darbar; John P Dimarco; Sandra B Dunbar; N A Mark Estes; T Bruce Ferguson; Stephen C Hammill; Pamela E Karasik; Mark S Link; Joseph E Marine; Mark H Schoenfeld; Amit J Shanker; Michael J Silka; Lynne Warner Stevenson; William G Stevenson; Paul D Varosy
Journal:  J Am Coll Cardiol       Date:  2012-09-10       Impact factor: 24.094

6.  The impact of left ventricular size on response to cardiac resynchronization therapy.

Authors:  John Rickard; Danielle M Brennan; David O Martin; Eileen Hsich; W H Wilson Tang; Bruce D Lindsay; Randall C Starling; Bruce L Wilkoff; Richard A Grimm
Journal:  Am Heart J       Date:  2011-09-14       Impact factor: 4.749

7.  Size Matters: Normalization of QRS Duration to Left Ventricular Dimensionzzm321990Improves Prediction of Long-Term Cardiac Resynchronizationzzm321990Therapy Outcome.

Authors:  Alwin Zweerink; Daniel J Friedman; Igor Klem; Peter M van de Ven; Caitlin Vink; P Stefan Biesbroek; Steen M Hansen; Kasper Emerek; Raymond J Kim; Albert C van Rossum; Brett D Atwater; Robin Nijveldt; Cornelis P Allaart
Journal:  Circ Arrhythm Electrophysiol       Date:  2018-12

Review 8.  The problem of non-response to cardiac resynchronization therapy.

Authors:  David H Birnie; Anthony Sl Tang
Journal:  Curr Opin Cardiol       Date:  2006-01       Impact factor: 2.161

9.  The influence of left ventricular ejection fraction on the effectiveness of cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy).

Authors:  Valentina Kutyifa; Axel Kloppe; Wojciech Zareba; Scott D Solomon; Scott McNitt; Slava Polonsky; Alon Barsheshet; Bela Merkely; Bernd Lemke; Vivien Klaudia Nagy; Arthur J Moss; Ilan Goldenberg
Journal:  J Am Coll Cardiol       Date:  2013-03-05       Impact factor: 24.094

10.  Durability of the survival effect of cardiac resynchronization therapy by level of left ventricular functional improvement: fate of "nonresponders".

Authors:  John Rickard; Alan Cheng; David Spragg; Sandeep Bansal; Mark Niebauer; Bryan Baranowski; Daniel J Cantillon; Patrick J Tchou; Richard A Grimm; W H Wilson Tang; Bruce L Wilkoff; Niraj Varma
Journal:  Heart Rhythm       Date:  2013-11-28       Impact factor: 6.343

View more
  2 in total

Review 1.  Mass Customized Outlook for Regenerative Heart Failure Care.

Authors:  Satsuki Yamada; Jozef Bartunek; Atta Behfar; Andre Terzic
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923

Review 2.  Cardiac Resynchronization Therapy in Non-Ischemic Cardiomyopathy: Role of Multimodality Imaging.

Authors:  Cristian Stătescu; Carina Ureche; Ștefana Enachi; Rodica Radu; Radu A Sascău
Journal:  Diagnostics (Basel)       Date:  2021-03-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.